top of page
About the Trial
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
Mechanism of Action:
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Carrie Harrison/Hannah Harrison
bottom of page